How AbbVie’s DECNUPAZ approval changes the treatment conversation in aggressive BPDCN
Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.
Can AbbVie’s Juvéderm strategy turn subtle aesthetics into the next growth engine for fillers
AbbVie is repositioning Juvéderm for the “undetectable” aesthetics era. Read what this means for injectables, clinicians, and market competition.
AbbVie’s AFFIRM trial: what clinicians should watch next for risankizumab in Crohn’s disease
AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma
AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.
Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum
Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.